Title: IMINOSUGARS AND METHODS OF TREATING ARENAVIRAL INFECTIONS

Abstract: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Arenaviridae family using iminosugars, such as DNJ derivatives.

Fig. 2
IMINOSUGARS AND METHODS OF TREATING ARENAVIRAL INFECTIONS

RELATED APPLICATIONS

The present application claims priority to U.S. provisional applications nos. 61/202,391 filed February 24, 2009 and 61/272,251 filed September 4, 2009, which are both incorporated by reference in their entirety.

FIELD

The present application relates to iminosugars and methods of treating viral infections with iminosugars and, in particular, to the use of iminosugars for treatment and prevention of viral infections caused by or associated with a virus belonging to the Arenaviridae family.

SUMMARY

One embodiment is a method of treating or preventing a disease or condition caused by or associated with a virus belonging to the Arenaviridae family, which method comprises administering to a subject in need thereof a compound of the formula,

\[
\begin{align*}
\text{W}_1 & \text{O} \\
\text{W}_2 & \text{O} \\
\text{W}_3 & \text{O} \\
\text{W}_4 & \\
\text{N} & \\
\text{R}
\end{align*}
\]

, wherein R is either selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted cycloalkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted oxaalkyl groups; or wherein R is
R₁ is a substituted or unsubstituted alkyl group;
X₁₋₅ are independently selected from H, NO₂, N₃, or NH₂;
Y is absent or is a substituted or unsubstituted C₁-alkyl group, other than carbonyl; and
Z is selected from a bond or NH; provided that when Z is a bond, Y is absent, and provided
that when Z is NH, Y is a substituted or unsubstituted C₁-alkyl group, other than carbonyl;
and
wherein W₁₋₄ are independently selected from hydrogen, substituted or unsubstituted alkyl
groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl
groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl
groups.

DRAWINGS

Figures 1(A)-(E) present chemical formulas of the following iminosugars: A) N-Butyl
deoxyojoirimycin (NB-DNJ or UV-1); B) N-Nonyl deoxyojoirimycin (NN-DNJ or UV-2); C)
N-(7-Oxadecyldideoxyojoirimycin (N7-O-DNJ or UV-3); D) N-(9-Methoxynonyl)
deoxyojoirimycin (N9-DNJ or UV-4); E) N-(N-{4'-azido-2'-nitrophenyl}-6-
aminoheptyldideoxyojoirimycin (NAP-DNJ or UV-5).

Figure 2 is a synthesis scheme for NN-DNJ.

Figures 3A-D illustrate synthesis of N7-O-DNJ. In particular, Figure 3A shows a sequence
of reactions leading to N7-O-DNJ; Figure 3B illustrates preparation of 6-propyloxy-1-
hexanol; Figure 3C illustrates preparation of 6-propyloxy-1-hexanal; Figure 3D illustrates
synthesis of N7-O-DNJ.

Figures 4A-C relate to synthesis of N-(9-Methoxynonyl) deoxyojoirimycin. In particular,
Figure 4A illustrates preparation of 9-methoxy-1-nonanol; Figure 4B illustrates preparation
of 9-methoxy-1-nonanal; Figure 4C illustrates synthesis of N-(9-Methoxynonyl)
deoxyojoirimycin.
Figure 5 presents data on the inhibition of Pichinde virus release by NB-DNJ; N7-O-DNJ and N9-DNJ.

Figure 6 presents activity of selected iminosugars against Pichinde virus (PICV) and Junin virus (JUNV).

Figure 7 presents antiviral activity of NB-DNJ, N7-O-DNJ and N9-DNJ against PICV. Figure 8 presents antiviral activity of NB-DNJ, NN-DNJ, N7-O-DNJ, N9-DNJ and NAP-DNJ against JUNV.

DETAILED DESCRIPTION

Definition of terms

Unless otherwise specified, “a” or “an” means “one or more.”

As used herein, the term “viral infection” describes a diseased state, in which a virus invades a healthy cell, uses the cell’s reproductive machinery to multiply or replicate and ultimately lyse the cell resulting in cell death, release of viral particles and the infection of other cells by the newly produced progeny viruses. Latent infection by certain viruses is also a possible result of viral infection.

As used herein, the term “treating or preventing viral infection” means to inhibit the replication of the particular virus, to inhibit viral transmission, or to prevent the virus from establishing itself in its host, and to ameliorate or alleviate the symptoms of the disease caused by the viral infection. The treatment is considered therapeutic if there is a reduction in viral load, decrease in mortality and/or morbidity.

IC50 or IC90 (inhibitory concentration 50 or 90) is a concentration of a therapeutic agent, such as an iminosugar, used to achieve 50% or 90% reduction of viral load, respectively.

Related Applications

The present application incorporates by reference in its entirety U.S. provisional application no. 61/202,391 filed February 24, 2009.
Disclosure

The present inventors discovered that certain iminosugars, such as deoxyajirimycin derivatives, can be effective against viruses belonging to the Arenaviridae family. In particular, the deoxyajirimycin derivatives can be useful for treating or preventing a disease or condition caused by or associated with a virus belonging to the Arenaviridae family.

Viruses belonging to the Arenaviridae family include arenaviruses belonging to the genus Arenavirus. Arenaviruses may cause a number of viral hemorrhagic fevers. The Arenavirus genus includes Lppy virus; Lassa virus; Lymphocytic choriomeningitis virus; Mobala virus; Mopeia virus; Amapari virus; Flexal virus; Guanarito virus; Junin virus; Latino virus; Machupo virus; Oliveros virus; Paraná virus; Pichinde virus; Pirital virus; Sabiá virus; Tacaribe virus; Tamiami virus; Whitewater Arroyo virus; and Chapare virus. Arenaviruses can be often transmitted by contact with rodents which can serve as the virus reservoir. Arenavirus infections can be endemic worldwide, and cause more than 1 million cases each year, with thousands of deaths. Pichinde virus, a member of the Arenavirus genus, which is not as dangerous to humans as other arenaviruses, is frequently used as a model in order to test activity of chemical compounds against this genus.

The diseases caused by or associated with arenaviruses include Lymphocytic choriomeningitis caused by Lymphocytic choriomeningitis virus; Lassa fever caused by Lassa virus; Argentine hemorrhagic fever caused by Junin virus; Bolivian hemorrhagic fever caused by Machupo virus; Venezuelan hemorrhagic fever caused by Guaranito virus; Brazilian hemorrhagic fever caused by Sabia virus; Tacaribe fever associated with Tacaribe virus; Influenza-like illness associated with Flexal virus; Hemorragic fever associated with Whitewater Arroyo virus.

In many embodiments, the iminosugar may be N-substituted deoxyajirimycin. In some embodiments, such N-substituted deoxyajirimycin may be a compound of the following formula:

-4-
where W₁₋₄ are independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups.

In some embodiments, R may be selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted cycloalkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted oxalkyl groups.

In some embodiments, R may be substituted or unsubstituted alkyl groups and/or substituted or unsubstituted oxalkyl groups comprise from 1 to 16 carbon atoms, from 4 to 12 carbon atoms or from 8 to 10 carbon atoms. The term “oxalkyl” refers to an alkyl derivative, which may contain from 1 to 5 or from 1 to 3 or from 1 to 2 oxygen atoms. The term “oxalkyl” includes hydroxyterminated and methoxyterminated alkyl derivatives.

In some embodiments, R may be selected from, but is not limited to -(CH₂)₆OCH₃, -(CH₂)₆OCH₂CH₃, -(CH₂)₆O(CH₂)₂CH₃, -(CH₂)₆O(CH₂)₃CH₃, -(CH₂)₂O(CH₂)₂CH₃, -(CH₂)₂O(CH₂)₃CH₃, -(CH₂)₂O(CH₂)₄CH₃, -(CH₂)₂O(CH₂)₅CH₃, -(CH₂)₂O(CH₂)₆CH₃, -(CH₂)₂O(CH₂)₇CH₃, -(CH₂)₂O(CH₂)₈CH₃, -(CH₂)₂O(CH₂)₉CH₃, -(CH₂)₂O(CH₂)₁₀CH₃, -(CH₂)₂O(CH₂)₁₁CH₃, -(CH₂)₂O(CH₂)₁₂CH₃, -(CH₂)₂O(CH₂)₁₃CH₃, -(CH₂)₂O(CH₂)₁₄CH₃, -(CH₂)₂O(CH₂)₁₅CH₃, -(CH₂)₂O(CH₂)₁₆CH₃, -(CH₂)₂O(CH₂)₁₇CH₃, -(CH₂)₂O(CH₂)₁₈CH₃, -(CH₂)₂O(CH₂)₁₉CH₃, -(CH₂)₂O(CH₂)₂₀CH₃.

In some embodiments, R may be branched or unbranched, substituted or unsubstituted alkyl group. In certain embodiments, the alkyl group may be a long chain alkyl group, which may be C₆-C₂₀ alkyl group; C₈-C₁₆ alkyl group; or C₈-C₁₀ alkyl group. In some embodiments, R may be a long chain oxalkyl group, i.e. a long chain alkyl group, which may contain from 1 to 5 or from 1 to 3 or from 1 to 2 oxygen atoms.
In some embodiments, R may have the following formula

![Chemical Structure](image)

, where R₁ is a substituted or unsubstituted alkyl group;
X₁₋₅ are independently selected from H, NO₂, N₃, or NH₂;
Y is absent or is a substituted or unsubstituted C₁-alkyl group, other than carbonyl; and
Z is selected from a bond or NH; provided that when Z is a bond, Y is absent, and provided
that when Z is NH, Y is a substituted or unsubstituted C₁-alkyl group, other than carbonyl.
In some embodiments, Z is NH and R₁-Y is a substituted or unsubstituted alkyl group, such
as C2-C20 alkyl group or C4-C12 alkyl group or C4-C10 alkyl group.
In some embodiments, X₁ is NO₂ and X₃ is N₃. In some embodiments, each of X₂, X₄ and X₅
is hydrogen.

In some embodiments, the iminosugar may be a DNJ derivative disclosed in U.S. Patent
application publication no. 2007/0275998, which is incorporated herein by reference.
In some embodiments, the deoxynojirimycin derivative may be one of the compounds
presented in Figure 1.

Methods of synthesizing deoxynojirimycin derivatives are disclosed, for example, in U.S.
Patent Nos. 5,622,972, 5,200,523, 5,043,273, 4,994,572, 4,246,345, 4,266,025, 4,405,714,
and 4,806,650 and U.S. Patent application publication no. 2007/0275998, which are all
incorporated herein by reference.

In some embodiments, the iminosugar may be in a form of a salt derived from an inorganic or
organic acid. Pharmaceutically acceptable salts and methods for preparing salt forms are
disclosed, for example, in Berge et al. (J. Pharm. Sci. 66:1-18, 1977). Examples of
appropriate salts include but are not limited to the following salts: acetate, adipate, alginate,
citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,
camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate,
glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrotate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

In some embodiments, the iminosugar may also used in a form of a prodrug. Prodrugs of DNJ derivatives, such as the 6-phosphorylated DNJ derivatives, are disclosed in U.S. Patents nos. 5,043,273 and 5,103,008.

In some embodiments, the iminosugar may be used as a part of a composition, which further comprises a pharmaceutically acceptable carrier and/or a component useful for delivering the composition to an animal. Numerous pharmaceutically acceptable carriers useful for delivering the compositions to a human and components useful for delivering the composition to other animals such as cattle are known in the art. Addition of such carriers and components to the composition of the invention is well within the level of ordinary skill in the art.

In some embodiments, the pharmaceutical composition may consist essentially of N-substituted deoxynojirimycin, which may mean that the N-substituted deoxynojirimycin is the only active ingredient in the composition.

Yet in some embodiments, N-substituted deoxynojirimycin may be administered with one or more additional antiviral compounds.

In some embodiments, the iminosugar may be used in a liposome composition, such as those disclosed in US publication 2008/0138351; US application No. 12/410,750 filed March 25, 2009 and US provisional application No. 61/202,699 filed March 27, 2009.

The iminosugar, such as a DNJ derivative, may be administered to a cell or an animal affected by a virus. The iminosugar may inhibit morphogenesis of the virus, or it may treat the individual. The treatment may reduce, abate, or diminish the virus infection in the animal.

Animals that may be infected with a virus that belongs to the Arenaviridae family, include vertebrates, such as birds and mammals including primates, humans, rodents and bats. The amount of iminosugar administered to an animal or to an animal cell to the methods of the invention may be an amount effective to inhibit the morphogenesis of a virus belonging to the Arenaviridae family from the cell. The term "inhibit" as used herein may refer to the detectable reduction and/or elimination of a biological activity exhibited in the absence of the
iminosugar. The term "effective amount" may refer to that amount of the iminosugar necessary to achieve the indicated effect. The term "treatment" as used herein may refer to reducing or alleviating symptoms in a subject, preventing symptoms from worsening or progressing, inhibition or elimination of the causative agent, or prevention of the infection or disorder related to the virus belonging to the Arenaviridae family in a subject who is free therefrom.

Thus, for example, treatment of the disease caused by or associated with a virus may include destruction of the infecting agent, inhibition of or interference with its growth or maturation, and neutralization of its pathological effects. The amount of the iminosugar which may be administered to the cell or animal is preferably an amount that does not induce any toxic effects which outweigh the advantages which accompany its administration.

Actual dosage levels of active ingredients in the pharmaceutical compositions may vary so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient.

The selected dose level may depend on the activity of the iminosugar, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound(s) at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, for example, two to four doses per day. It will be understood, however, that the specific dose level for any particular patient may depend on a variety of factors, including the body weight, general health, diet, time and route of administration and combination with other therapeutic agents and the severity of the condition or disease being treated. The adult human daily dosage may range from between about one microgram to about one gram, or from between about 10 mg and 100 mg, of the iminosugar per 10 kilogram body weight. Of course, the amount of the iminosugar which should be administered to a cell or animal may depend upon numerous factors well understood by one of skill in the art, such as the molecular weight of the iminosugar and the route of administration.

Pharmaceutical compositions that are useful in the methods of the invention may be administered systemically in oral solid formulations, ophthalmic, suppository, aerosol, topical
or other similar formulations. For example, it may be in the physical form of a powder, tablet, capsule, lozenge, gel, solution, suspension, syrup, or the like. In addition to the iminosugar, such pharmaceutical compositions may contain pharmaceutically-acceptable carriers and other ingredients known to enhance and facilitate drug administration. Other possible formulations, such as nanoparticles, liposomes, resealed erythrocytes, and immunologically based systems may also be used to administer the iminosugar. Such pharmaceutical compositions may be administered by a number of routes. The term "parenteral" used herein includes subcutaneous, intravenous, intraarterial, intrathecal, and injection and infusion techniques, without limitation. By way of example, the pharmaceutical compositions may be administered orally, topically, parenterally, systemically, or by a pulmonary route.

These compositions may be administered a in a single dose or in multiple doses which are administered at different times. Because the inhibitory effect of the composition upon a virus belonging to the Arenaviridae family may persist, the dosing regimen may be adjusted such that virus propagation is retarded while the host cell is minimally effected. By way of example, an animal may be administered a dose of the composition of the invention once per week, whereby virus propagation is retarded for the entire week, while host cell functions are inhibited only for a short period once per week.

Embodiments described herein are further illustrated by, though in no way limited to, the following working examples.

Working Examples

1. Synthesis of N-Nonyl DNJ

Table 1. Materials for NN-DNJ synthesis

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNJ</td>
<td>500 mg</td>
</tr>
<tr>
<td>Nonanal</td>
<td>530 mg</td>
</tr>
<tr>
<td>Ethanol</td>
<td>100 mL</td>
</tr>
<tr>
<td>AcOH</td>
<td>0.5 mL</td>
</tr>
</tbody>
</table>
Pd/C | 500 mg

Procedure: A 50-mL, one-necked, round-bottom flask equipped with a magnetic stirrer was charged with DNJ (500 mg), ethanol (100 mL), nonanal (530 mg), and acetic acid (0.5 mL) at room temperature. The reaction mixture was heated to 40-45 °C and stirred for 30-40 minutes under nitrogen. The reaction mixture was cooled to ambient temperature and Pd/C was added. The reaction flask was evacuated and replaced by hydrogen gas in a balloon. This process was repeated three times. Finally, the reaction mixture was stirred at ambient temperature overnight. The progress of reaction was monitored by TLC (Note 1). The reaction mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated in vacuo to get the crude product. The crude product was purified by column chromatography (230-400 mesh silica gel). A solvent gradient of methanol in dichloromethane (10-25%) was used to elute the product from the column. All fractions containing the desired product were combined, and concentrated in vacuo to give the pure product (420mg). Completion of the reaction was monitored by thin layer chromatography (TLC) using a thin layer silica gel plate; eluent; methanol : dichloromethane = 1:2

2. Synthesis of N-7-Oxadecyl DNJ

2a. Synthesis of 6-propyloxy-1-hexanol

Table 2. Materials for synthesis of 6-propyloxy-1-hexanol

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,6-hexanediol</td>
<td>6.00 g</td>
</tr>
<tr>
<td>1-Iodopropane</td>
<td>8.63 g</td>
</tr>
<tr>
<td>Potassium tert-butoxide</td>
<td>5.413 mg</td>
</tr>
<tr>
<td>THF</td>
<td>140 mL</td>
</tr>
</tbody>
</table>

Procedure: a 500-mL, one-necked, round-bottom flask equipped with a magnetic stirrer was charged with 1,6-hexanediol (6.00 g), potassium tert-butoxide (5.413 g) at room temperature. The reaction mixture was stirred for one hour, and then 1-iodopropane (8.63 g) was added. The reaction mixture was heated to 70-80 °C and stirred overnight. The progress of reaction
was monitored by TLC (Note 1). After completion of the reaction, water was added to the reaction mixture, and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were concentrated in vacuo to get the crude product. The crude product was dissolved in dichloromethane and washed with water, and then brine, dried over sodium sulfate. The organic layer was concentrated in vacuo to get the crude product. The crude product was purified by column chromatography using 230-400 mesh silica gel. A solvent gradient of ethyl acetate in hexanes (10-45%) was used to elute the product from the column. All fractions containing the desired pure product were combined and concentrated in vacuo to give pure 6-propyloxy-1-hexanol (lot D-1029-048, 1.9 g, 25%) Completion of the reaction was monitored by thin layer chromatography (TLC); (eluent: 60% ethyl acetate in hexanes).

2b. Preparation of 6-propyloxy-1-hexanal

Table 3. Materials for preparation of 6-propyloxy-1-hexanal

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-Propyloxy-1-hexanol</td>
<td>1.00 g</td>
</tr>
<tr>
<td>PDC</td>
<td>4.70 g</td>
</tr>
<tr>
<td>Celite</td>
<td>1.00 g</td>
</tr>
<tr>
<td>NaOAc</td>
<td>100 mg</td>
</tr>
<tr>
<td>CH₂Cl₂</td>
<td>10 mL</td>
</tr>
</tbody>
</table>

Procedure: a 50-mL, one-necked, round-bottom flask equipped with a magnetic stirrer was charged with 6-propyloxy-1-hexanol (1.0 g), PDC (4.7 g), dichloromethane (10 mL), Celite (1.0 g), and sodium acetate (100 mg). The reaction mixture was stirred at room temperature under nitrogen for 5 minutes. PDC (4.70 g) was added to the reaction mixture, and stirred overnight. The progress of reaction was monitored by TLC (Note 1). After completion of the reaction, the reaction mixture was directly loaded on the column (230-400 mesh silica gel). A solvent gradient of dichloromethane in ethyl acetate (10-20%) was used to elute the product from the column. All fractions containing the desired pure product were combined and concentrated in vacuo to give pure 6-propyloxy-1-hexanal (lot D-1029-050, 710 mg,
71%). Completion of the reaction was monitored by thin layer chromatography (TLC); (eluent: 60% ethyl acetate in hexanes).

2c Synthesis of N-7-Oxadecyl-DNJ

Table 4. Materials for Synthesis of N-7-Oxadecyl-DNJ

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNJ</td>
<td>500 mg</td>
</tr>
<tr>
<td>6-Propyloxy-1-hexanal</td>
<td>585 mg</td>
</tr>
<tr>
<td>Pd/C</td>
<td>125 mg</td>
</tr>
<tr>
<td>Ethanol</td>
<td>15 mL</td>
</tr>
<tr>
<td>Acetic acid</td>
<td>mL</td>
</tr>
</tbody>
</table>

Procedure: a 50-mL, one-necked, round-bottom flask equipped with a magnetic stirrer was charged with DNJ (500 mg), ethanol (15 mL), 6-propyloxy-1-hexanal (585 mg), and acetic acid (0.1mL) at room temperature. The reaction mixture was heated to 40-45 °C and stirred for 30-40 minutes under nitrogen. The reaction mixture was cooled to ambient temperature and Pd/C was added. The reaction flask was evacuated and replaced by hydrogen gas in a balloon. This process was repeated three times. Finally, the reaction mixture was stirred at ambient temperature overnight. The progress of reaction was monitored by TLC (Note 1). The reaction mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated in vacuo to get the crude product. The crude product was purified by column chromatography (230-400 mesh silica gel). A solvent gradient of methanol in dichloromethane (10-40%) was used to elute the product from the column. All fractions containing the desired product were combined, and concentrated in vacuo to give the pure product. (Lot: D-1029-052 (840 mg). Completion of the reaction was monitored by thin layer chromatography (TLC); (eluent: 50% methanol in dichloromethane).

3. Synthesis of N-(9-methoxy)-nonyl DNJ

3a Preparation of 9-methoxy-1-nonanol

Table 5. Materials for preparation of 9-methoxy-1-nonanol
<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,9-nonanediol</td>
<td>10.0 g</td>
</tr>
<tr>
<td>Dimethyl sulfate</td>
<td>41.39 g</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>5.0 g</td>
</tr>
<tr>
<td>DMSO</td>
<td>100 mL</td>
</tr>
</tbody>
</table>

Procedure: a 500-mL, one-necked, round-bottom flask equipped with a magnetic stirrer and stir bar was charged with 1,9-nonanediol (10.00 g, 62.3 mmol) in dimethyl sulfoxide (100 mL) and H₂O (100 mL). To this was added slowly a solution of sodium hydroxide (5.0 g, 125.0 mmol) in H₂O (10 mL) at room temperature. During addition of sodium hydroxide the reaction mixture generated heat and the temperature rose to ~40 °C. The mixture was stirred for one hour, and then dimethyl sulfate (16.52 g, 131 mmol) was added in four portions while maintaining the temperature of the reaction mixture at ~ 40°C. The reaction mixture was stirred at room temperature overnight. Progress of the reaction was monitored by TLC (Note 1). TLC monitoring indicated that the reaction was 25 % conversion. At this stage additional dimethyl sulfate (24.78g, 196.44 mmol) was added and the resulting mixture was stirred at room temperature for an additional 24 h. After completion of the reaction, sodium hydroxide (10% solution in water) was added to the reaction mixture to adjust the pH of the solution to 11-13. The mixture was stirred at room temperature for 2 h and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with H₂O (200 mL), brine (150 mL), dried over anhydrous sodium sulfate (20 g), filtered and concentrated in vacuo to obtain a crude product (14 g). The crude product was purified by column chromatography using 250-400 mesh silica gel. A solvent gradient of ethyl acetate in hexanes (10-50%) was used to elute the product from the column. All fractions containing the desired pure product were combined and concentrated in vacuo to give pure 9-methoxy-1-nonanol (lot D-1027-155, 2.38 g, 21.9 %). Completion of the reaction was monitored by thin layer chromatography (TLC) using a thin layer silica gel plate; eluent: 60% ethyl acetate in hexanes.
3b Preparation of 9-methoxy-1-nonanal

Table 6. Materials for preparation of 9-methoxy-1-nonanal

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-methoxy-1-nonanol</td>
<td>1.0 g</td>
</tr>
<tr>
<td>PDC</td>
<td>4.7 g</td>
</tr>
<tr>
<td>Molecular sieves, 3A</td>
<td>1.0 g</td>
</tr>
<tr>
<td>NaOAc</td>
<td>0.1 g</td>
</tr>
<tr>
<td>CH$_2$Cl$_2$</td>
<td>10 mL</td>
</tr>
</tbody>
</table>

Procedure: a 50-mL, one-necked, round-bottom flask equipped with a magnetic stirrer and stir bar was charged with 9-methoxy-nonanol (1.0 g, 5.9 mmol), dichloromethane (10 mL), molecular sieves (1.0 g, 3A), sodium acetate (0.1 g) at room temperature. The reaction mixture was stirred at room temperature under nitrogen for 5 minutes. The reaction mixture was charged with pyridinium dichromate (4.7 g, 12.5 mmol) and stirred overnight. The progress of reaction was monitored by TLC (Note 1). After completion of the reaction, the reaction mixture was filtered through a bed of silica gel (~15 g). The filtrate was evaporated in vacuo to obtain a crude compound. This was purified by column chromatography using silica gel column (250-400 mesh, 40 g). A solvent gradient of ethyl acetate in hexane (10-50%) was used to elute the product from the column. All fractions containing the desired pure product were combined and concentrated in vacuo to give pure 9-methoxy-nonanal (lot D-1027-156, 553 mg, 54.4%). Completion of the reaction was monitored by thin layer chromatography (TLC) using a thin layer silica gel plate; eluent: 60% ethyl acetate in hexanes.

3c Synthesis of N-(9-methoxy)-nonyl DNJ

Table 7. Materials for synthesis of N-(9-methoxy)-nonyl DNJ

<table>
<thead>
<tr>
<th>Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNJ</td>
<td>300 mg</td>
</tr>
<tr>
<td>9-methoxy-1-nonanal</td>
<td>476 mg</td>
</tr>
</tbody>
</table>
Procedure: a 50-mL, two-necked, round-bottom flask equipped with magnetic stirrer and a stir bar was charged with DNJ (300 mg, 1.84 mmol), ethanol (20 mL), 9-methoxy-1-nonanal (476 mg, 2.76 mmol) at room temperature. The reaction mixture was stirred for 5-10 minutes under nitrogen and Pd/C was added at room temperature. The reaction mixture was evacuated and was replaced by hydrogen gas using a balloon. This process was repeated three times and then reaction mixture was stirred under atmospheric hydrogen at room temperature. The progress of reaction was monitored by TLC (Note 1). The reaction mixture was filtered through a bed of Celite and was washed with ethanol (20 mL). The filtrate was concentrated in vacuo to get a crude product. The crude product was purified by column chromatography using 250-400 mesh silica gel (20 g). A solvent gradient of methanol in ethyl acetate (5-25%) was used to elute the product from the column. All fractions containing the desired pure product were combined, and concentrated in vacuo to give an off white solid. The solid was triturated in ethyl acetate (20 mL), filtered and dried in high vacuum to give a white solid [lot: D-1027-158 (165.3 mg, 28.1%). Completion of the reaction was monitored by thin layer chromatography (TLC) using a thin layer silica gel plate; eluent: 50% methanol in dichloromethane.

4. Effect of iminosugars against Pichinde Virus

Figure 5 presents data on the inhibition of Pichinde virus release by the following UV iminosugar compounds: NB-DNJ (UV-1); NN-DNJ (UV-2); N7-O-DNJ (UV-3); N9-DNJ (UV-4); NAP-DNJ (UV-5). Control Vero cell cultures and Vero cell cultures treated with 100μM compounds were infected with virus and cultured for 7 days at 37°C in a 5% CO2 incubator. Inhibition of production of infectious virus particles from virus infected cell cultures treated with compounds were determined by plaque assay. The virus plaque assay was performed in Vero cells plated in 6-well plates at 5x10^5 cells per well in 1x modified Eagle medium (Gibco), supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin. The virus to be titered from collected supernatants from infected cell cultures treated with the compounds were diluted in
cell culture medium and inoculated in 100 μl volumes onto cells and allowed to adsorb for 1 hr at 37°C. The cells were overlaid with 0.6% agarose in 1x modified Eagle medium (Gibco), supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin. Plaques, of dead cells representing individual infectious virus particles that has infected and killed cells, were allowed to develop at 37°C in a 5% CO2 incubator and visualized by live-staining the cell monolayer with neutral red. The experiment demonstrates that release of infectious Pichinde virus is significantly reduced after treatment with UV iminosugar compounds.

5. Effects of iminosugars against Pichinde and Junin viruses

Figure 6 presents data on the inhibition of Pichinde virus and Junin virus releases by the following UV iminosugar compounds: NB-DNJ (UV-1); NN-DNJ (UV-2); N7-O-DNJ (UV-3); N9-DNJ (UV-4); NAP-DNJ (UV-5).

Compounds. Base stocks of the following compounds were prepared in dimethylsulfoxide (DMSO) to a final maximal DMSO concentration of 0.5%: UV-1, UV-2, UV-3, UV-4, and UV-5. All compounds were diluted from the base stocks to their experimental concentrations.

Viruses. The compounds were screened for inhibition against Pichinde Virus ( Arenavirus) CoAn 3739 strain, and the Junin ( Arenavirus) Candid #1 strain. Viral stocks were made by propagation in Vero cells using modified Eagle medium (MEM, Sigma), supplemented with 2% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and titered using the standard plaque assay (method presented below). Viral stocks were stored at -80°C until used.

Virus Yield Reduction Assay. The virus yield assay were performed by standard plaque assay on supernatant samples generated from virus-infected cells incubated with different concentrations of iminosugars. 24-well cell culture plates were seeded with cells in 1mL MEM with 10% fetal bovine serum Vero cells (ATCC, Mannassas, VA; ATCC number CCL-81) in MEM with Earl’s salts (Sigma, St Louis, MO) supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and 2% heat-inactivated fetal bovine serum and incubated at 37°C for 24 hours or until ~80% confluency. Medium were replaced with medium supplemented with 2% fetal bovine serum and the compound concentrations to be
used started at 500 μM, 250 μM or 125 μM and tested in triplicate using 8 dilutions. Compounds are added to appropriate wells and incubated for 1hr at 37°C, 5% CO₂. After 1hr incubation virus is added to each well. Four days are required for the PICV and five days for JUNV virus infection. Upon completion of infection, supernatant were collected for titering. To titer PICV and JUNV, 12-well plates with 80% confluent Vero cells in growth medium were used. Viral supernatant were diluted from 10⁻³ to 10⁻⁸ and added (100uL) to the cells and incubated at 37°C for 1 hour with shaking every 5-10 minutes. Viral infection medium (100uL) were aspirated and replace with 1mL pre-warmed 2% low-melt agarose mixed 1:1 with 2X MEM (5% fetal calf serum) and incubated at 37°C, 5% CO₂ for 6 days followed by plaque visualization by neutral red staining. IC 50 was determined as concentration of compound resulting in 50% virus inhibition.

Figure 7 compares inhibition of Pichinde virus for control, UV-1, UV-3 and UV-4.

Compounds. Base stocks of the following compounds were prepared in dimethylsulfoxide (DMSO) to a final maximal DMSO concentration of 0.5%: UV-1, UV-2, UV-3, UV-4, UV-5. All compounds were diluted from the base stocks to their experimental concentrations.

Virus. The compounds were screened for inhibition against the Pichinde virus CoAn 3739 strain.

Results: The virus yield assay were performed as described above. PICV CoAn 3739 strain virus inhibition was found for compounds NB-DNJ, N7-O-DNJ, and N9-DNJ. PICV in vitro inhibition resulted in over 50% inhibition by NB-DNJ, 70% inhibition by N7-O-DNJ and over 99% inhibition by N9-DNJ at a 100 μM iminosugar concentration.

Figure 8 shows inhibition plots for Junin virus by UV-1, UV-2, UV-3, UV-4 and UV-5 iminosugars as percentage of viral infectivity compared with control versus concentration of iminosugar compound.

Compounds. Base stocks of the following compounds were prepared in dimethylsulfoxide (DMSO) to a final maximal DMSO concentration of 0.5%: UV-1, UV-2, UV-3, UV-4, UV-5. All compounds were diluted from the base stocks to their experimental concentrations.

Virus. The compounds were screened against the Junin virus Candid #1 strain.

Results: The virus yield assay were performed as described above. Junin virus inhibition was found for compounds NB-DNJ with an EC50 of 350 μM. NN-DNJ with an EC50 of 60 μM,
and NAP-DNJ showed protection with and EC50 of 10 μM. Compounds N7-O-DNJ and N9-DNJ had EC50s over 500 μM.

***

Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention.

All of the publications, patent applications and patents cited in this specification are incorporated herein by reference in their entirety.
WHAT IS ClaimED IS:

1. A method of treating or preventing a disease or condition caused by or associated with a virus belonging to the Arenaviridae family, the method comprising administering to a subject in need thereof an effective amount of a compound of the formula,

\[
\begin{align*}
\text{W}_1 & \text{O} \\
\text{W}_2 & \text{O} \\
\text{N} & \text{W}_3 \\
\text{R} & \text{W}_4
\end{align*}
\]

, or a pharmaceutically acceptable salt thereof,

wherein R is either selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted cycloalkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted oxaaalkyl groups; or wherein R is

\[
\begin{align*}
\text{R}_1 & -\text{Y} - \text{Z} - \text{X}_3 \\
& \text{X}_1 \quad \text{X}_2 \\
& \text{X}_5 \quad \text{X}_4
\end{align*}
\]

R\(_1\) is a substituted or unsubstituted alkyl group;
X\(_{1-5}\) are independently selected from H, NO\(_2\), N\(_3\), or NH\(_2\);
Y is absent or is a substituted or unsubstituted C\(_1\)-alkyl group, other than carbonyl; and
Z is selected from a bond or NH; provided that when Z is a bond, Y is absent, and provided that when Z is NH, Y is a substituted or unsubstituted C\(_1\)-alkyl group, other than carbonyl; and

wherein W\(_{1-4}\) are independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups.
2. The method of claim 1, wherein each of $W_1$, $W_2$, $W_3$ and $W_4$ is hydrogen.

3. The method of claim 1, wherein $R$ is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted cycloalkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted oxoalkyl groups.

4. The method of claim 1, wherein $R$ is C2-C12 alkyl group.

5. The method of claim 1, wherein $R$ is C3-C6 alkyl group.

6. The method of claim 1, wherein said administering comprises administering B-butyl deoxynojirimycin or a pharmaceutically acceptable salt thereof.

7. The method of claim 1, wherein $R$ is an oxoalkyl group.

8. The method of claim 1, wherein $R$ is C2-C16 oxoalkyl group that contains from 1 to 3 oxygen atoms.

9. The method of claim 1, wherein $R$ is C6-C12 oxoalkyl group that contains from 1 to 2 oxygen atoms.

10. The method of claim 1, wherein said administering comprises administering N-(7-oxadecyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein said administering comprises administering is N-(9-Methoxynonyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.

12. The method of claim 1, wherein $R$ is

13. The method of claim 12, wherein $X_1$ is NO$_2$ and $X_3$ is N$_3$.

14. The method of claim 12, wherein each of $X_2$, $X_4$ and $X_5$ is hydrogen.
15. The method of claim 1, wherein said administering comprises administering is N-(N-\{4'-azido-2'-nitrophenyl\}-6-aminohexyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.

16. The method of claim 1, wherein the subject is a mammal.

17. The method of claim 1, wherein the subject is a human being.

18. The method of claim 1, wherein the virus is selected from Ippy virus; Lassa virus; Lymphocytic choriomeningitis virus; Mobala virus; Mopeia virus; Amapari virus; Flexal virus; Guanarito virus; Junin virus; Latino virus; Machupo virus; Oliveros virus; Paraná virus; Pichinde virus; Pirital virus; Sabiá virus; Tacaribe virus; Tamiami virus; Whitewater Arroyo virus; and Chapare virus.

19. The method of claim 1, wherein the virus is Pichinde virus.

20. The method of claim 1, wherein the virus is Junin virus.

21. The method of claim 1, wherein the disease or condition is selected from Lymphocytic choriomeningitis; Lassa fever; Argentine hemorrhagic fever; Bolivian hemorrhagic fever; Brazilian hemorrhagic fever; Tacaribe fever; Venezuelan hemorrhagic fever; Influenza-like illness associated with Flexal virus; and Hemorrhagic fever associated with Whitewater Arroyo virus.

22. The method of claim 1, wherein the disease or conditions is Argentine hemorrhagic fever.

23. The method of claim 1, wherein the disease or conditions is Lassa fever.
Fig. 5

Arenavirus (Pichinde) results
- Virus release, % of control
- Drug concentration 100 µM

![Bar chart showing virus release results for different groups: Ctrl, NB-DNJ, N7-DNJ, N9-DNJ.](chart_image)
### Fig. 6

**Activity vs. Arenavirus**

<table>
<thead>
<tr>
<th>Compound</th>
<th>PICV (Virus Infectivity @ 100uM compound conc. IC50 uM)</th>
<th>JUNV (Virus Infectivity @ 100uM compound conc. IC50 uM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UV-1</td>
<td>47.0% &gt;250</td>
<td>100.0% 350</td>
</tr>
<tr>
<td>UV-2</td>
<td>-- --</td>
<td>8.0% 60</td>
</tr>
<tr>
<td>UV-3</td>
<td>30.0% &gt;250</td>
<td>80.0% &gt;500</td>
</tr>
<tr>
<td>UV-4</td>
<td>0.6% --</td>
<td>100.0% &gt;500</td>
</tr>
<tr>
<td>UV-5</td>
<td>-- 40</td>
<td>0.2% 10</td>
</tr>
</tbody>
</table>

*Abbreviations: PICV - Pichinde virus; JUNV - Junin virus; -- - Data not available*
Fig. 7

ANTIVIRAL ACTIVITY: PICHINDE VIRUS
Virus infectivity, % control, @100 uM compound concentration

In vitro

120
100
80
60
40
20
0

Control  UV-1  UV-3  UV-4

100.0%
47.0%
30.0%
0.6%
ANTIVIRAL ACTIVITY: JUNIN VIRUS

Virus infectivity, % control

Compound concentration, uM (log scale)

Fig. 8

SUBSTITUTE SHEET (RULE 26)
### INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

- IPC(8) - A01N 43/40; A61K 31/445 (2010.01)
- USPC - 514/317

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

- USPC - 514/317

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

- USPC - 514/315; 514/319; 514/327 (see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)


**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 2007/0275998 A1 (BUTTERS et al.) 29 November 2007 (29.11.2007) para [0031], [0033], [0048], [0049], [0071]-[0080], [0126], [0137]</td>
<td>1-23</td>
</tr>
<tr>
<td>Y</td>
<td>WO 2006/124976 A1 (KOHN et al.) 23 November 2006 (23.11.2006) para [0071], [0090], [0092], [0129], [0168], [0209]</td>
<td>1-23</td>
</tr>
</tbody>
</table>

Additional information:

- *: Special categories of cited documents:
  - "A": Document defining the general state of the art which is not considered to be of particular relevance
  - "E": Earlier application or patent published on or after the international filing date
  - "L": Document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O": Document referring to an oral disclosure, use, exhibition or other means
  - "P": Document published prior to the international filing date but later than the priority date claimed

- "T": Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X": Document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y": Document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to person skilled in the art
- "G": Document member of the same patent family

**Date of the actual completion of the international search**

19 March 2010 (19.03.2010)

**Date of mailing of the international search report**

07 APR 2010

**Name and mailing address of the ISA/US**

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

**Authorized officer:**

Lee W. Young

PCT Helpline: 571-272-4300
PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (July 2009)